http://dgnews.docguide.com/higher-brain-glucose-levels-may-mean-more-severe-alzheimer-s?
BETHESDA,
Md -- November 6, 2017 -- For the first time, researchers have found a
connection between abnormalities in how the brain breaks down glucose
and the severity of the signature amyloid plaques and tangles in the
brain, as well as the onset of eventual outward symptoms, of Alzheimer’s
disease.
The study is published in the November 6, 2017, issue of Alzheimer's & Dementia.
Madhav Thambisetty, MD, Unit of Clinical and Translational Neuroscience in the NIA’s Laboratory of Behavioral Neuroscience, Bethesda, Maryland, and colleagues looked at brain tissue samples at autopsy from participants in the Baltimore Longitudinal Study of Aging (BLSA), one of the world’s longest-running scientific studies of human aging. The BLSA tracks neurological, physical and psychological data on participants over several decades.
The researchers measured glucose levels in different brain regions, some vulnerable to Alzheimer’s disease pathology, such as the frontal and temporal cortex, and some that are resistant, like the cerebellum. They analysed 3 groups of BLSA participants: those with Alzheimer’s symptoms during life and with confirmed Alzheimer’s disease pathology (beta-amyloid protein plaques and neurofibrillary tangles) in the brain at death; healthy controls; and individuals without symptoms during life but with significant levels of Alzheimer’s pathology found in the brain post-mortem.
They found distinct abnormalities in glycolysis, with evidence linking the severity of the abnormalities to the severity of Alzheimer’s pathology. Lower rates of glycolysis and higher brain glucose levels correlated to more severe plaques and tangles found in the brains of people with the disease. More severe reductions in brain glycolysis were also related to the expression of symptoms of Alzheimer’s disease during life, such as problems with memory.
“For some time, researchers have thought about the possible links between how the brain processes glucose and Alzheimer’s,” said Richard J. Hodes, MD, NIA. “Research such as this involves new thinking about how to investigate these connections in the intensifying search for better and more effective ways to treat or prevent Alzheimer’s disease.”
While similarities between diabetes and Alzheimer’s have long been suspected, they have been difficult to evaluate, since insulin is not needed for glucose to enter the brain or to get into neurons. The team tracked the brain’s usage of glucose by measuring ratios of the amino acids serine, glycine and alanine to glucose, allowing them to assess rates of the key steps of glycolysis.
They found that the activities of enzymes controlling these key glycolysis steps were lower in Alzheimer’s cases compared with normal brain tissue samples. Furthermore, lower enzyme activity was associated with more severe Alzheimer’s pathology in the brain and the development of symptoms.
Next, the researchers used proteomics to tally levels of the glucose transporter protein GLUT3 in neurons. They found that GLUT3 levels were lower in brains with Alzheimer’s pathology compared with normal brains, and that these levels were also connected to the severity of tangles and plaques. Finally, the team checked blood glucose levels in study participants years before they died, finding that greater increases in blood glucose levels correlated with greater brain glucose levels at death.
“These findings point to a novel mechanism that could be targeted in the development of new treatments to help the brain overcome glycolysis defects in Alzheimer’s disease,” said Dr. Thambisetty.
The researchers cautioned that it is not yet completely clear whether abnormalities in brain glucose metabolism are definitively linked to the severity of Alzheimer’s disease symptoms or the speed of disease progression. The next steps for the team includes studying abnormalities in other metabolic pathways linked to glycolysis to determine how they may relate to Alzheimer’s pathology in the brain.
Reference: doi: 10.1016/j.jalz.2017.09.011
SOURCE: National Institutes of Health
The study is published in the November 6, 2017, issue of Alzheimer's & Dementia.
Madhav Thambisetty, MD, Unit of Clinical and Translational Neuroscience in the NIA’s Laboratory of Behavioral Neuroscience, Bethesda, Maryland, and colleagues looked at brain tissue samples at autopsy from participants in the Baltimore Longitudinal Study of Aging (BLSA), one of the world’s longest-running scientific studies of human aging. The BLSA tracks neurological, physical and psychological data on participants over several decades.
The researchers measured glucose levels in different brain regions, some vulnerable to Alzheimer’s disease pathology, such as the frontal and temporal cortex, and some that are resistant, like the cerebellum. They analysed 3 groups of BLSA participants: those with Alzheimer’s symptoms during life and with confirmed Alzheimer’s disease pathology (beta-amyloid protein plaques and neurofibrillary tangles) in the brain at death; healthy controls; and individuals without symptoms during life but with significant levels of Alzheimer’s pathology found in the brain post-mortem.
They found distinct abnormalities in glycolysis, with evidence linking the severity of the abnormalities to the severity of Alzheimer’s pathology. Lower rates of glycolysis and higher brain glucose levels correlated to more severe plaques and tangles found in the brains of people with the disease. More severe reductions in brain glycolysis were also related to the expression of symptoms of Alzheimer’s disease during life, such as problems with memory.
“For some time, researchers have thought about the possible links between how the brain processes glucose and Alzheimer’s,” said Richard J. Hodes, MD, NIA. “Research such as this involves new thinking about how to investigate these connections in the intensifying search for better and more effective ways to treat or prevent Alzheimer’s disease.”
While similarities between diabetes and Alzheimer’s have long been suspected, they have been difficult to evaluate, since insulin is not needed for glucose to enter the brain or to get into neurons. The team tracked the brain’s usage of glucose by measuring ratios of the amino acids serine, glycine and alanine to glucose, allowing them to assess rates of the key steps of glycolysis.
They found that the activities of enzymes controlling these key glycolysis steps were lower in Alzheimer’s cases compared with normal brain tissue samples. Furthermore, lower enzyme activity was associated with more severe Alzheimer’s pathology in the brain and the development of symptoms.
Next, the researchers used proteomics to tally levels of the glucose transporter protein GLUT3 in neurons. They found that GLUT3 levels were lower in brains with Alzheimer’s pathology compared with normal brains, and that these levels were also connected to the severity of tangles and plaques. Finally, the team checked blood glucose levels in study participants years before they died, finding that greater increases in blood glucose levels correlated with greater brain glucose levels at death.
“These findings point to a novel mechanism that could be targeted in the development of new treatments to help the brain overcome glycolysis defects in Alzheimer’s disease,” said Dr. Thambisetty.
The researchers cautioned that it is not yet completely clear whether abnormalities in brain glucose metabolism are definitively linked to the severity of Alzheimer’s disease symptoms or the speed of disease progression. The next steps for the team includes studying abnormalities in other metabolic pathways linked to glycolysis to determine how they may relate to Alzheimer’s pathology in the brain.
Reference: doi: 10.1016/j.jalz.2017.09.011
SOURCE: National Institutes of Health
No comments:
Post a Comment